News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CardioGenics Holdings Inc. Announces Schedule for Beta-Site Testing



7/10/2013 9:10:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MISSISSAUGA, Ontario, July 10, 2013 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care™ Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES